CDK8/19-IN-2

CDK8/19-IN-2 (compound 12) is an orally active and potent cyclin-dependent kinase 8/19 (CDK8 and CDK19) inhibitor, with IC50 values of 2.08 and 2.49 nM, respectively. CDK8/19-IN-2 can be used for acute myeloid leukemia (AML), breast cancer, and lymphoma research[1].

Product Specifications

CAS Number

[3024381-54-9]

UNSPSC

12352005

Target

CDK; STAT

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; JAK/STAT Signaling; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cdk8-19-in-2.html

Smiles

BrC1=C(C=C2N(C(N3CCNCC3)=NC2=C1C(F)F)C4CCOCC4)Br

Molecular Formula

C17H20Br2F2N4O

Molecular Weight

494.17

References & Citations

[1]Xu J, et al. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer. J Med Chem. 2024 May 23;67 (10) :8161-8171.